93 filings
8-K
ENTA
Enanta Pharmaceuticals Inc
12 Mar 24
Departure of Directors or Certain Officers
4:00pm
8-K
ENTA
Enanta Pharmaceuticals Inc
7 Feb 24
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024
4:05pm
8-K
ENTA
Enanta Pharmaceuticals Inc
26 Dec 23
Departure of Directors or Certain Officers
4:06pm
8-K
ENTA
Enanta Pharmaceuticals Inc
20 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
ENTA
Enanta Pharmaceuticals Inc
7 Aug 23
Results of Operations and Financial Condition
4:06pm
8-K
1mcbt4rnw3k5emsxjf
7 Jun 23
Regulation FD Disclosure
7:01am
8-K
sm6crvgwqbx ujrlsdlv
8 May 23
Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million
4:06pm
8-K
83fg f4jw
27 Apr 23
Non-Dilutive and Strengthens Balance Sheet
4:43pm
8-K
nc8 5uju5qr
10 Mar 23
Regulation FD Disclosure
4:43pm
8-K
s7ni cci935mqpkjqwn
7 Mar 23
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
ldtu269
7 Feb 23
Results of Operations and Financial Condition
4:06pm
8-K
ckcg2iopla7vg1enjwt4
21 Nov 22
Results of Operations and Financial Condition
4:08pm
8-K
d59hgd7nfmkg6ncb6v
26 Aug 22
Entry into a Material Definitive Agreement
4:10pm
8-K
0ffqscap
8 Aug 22
Results of Operations and Financial Condition
4:04pm
8-K
cfc10lud bu
22 Jun 22
Other Events
6:22am
8-K
vaqu6aw
17 May 22
Entry into a Material Definitive Agreement
4:37pm
8-K
excmci8unzgjg
9 May 22
Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter
4:00pm
8-K
hlfe2le
9 Mar 22
Departure of Directors or Certain Officers
4:03pm
8-K
cm97o n6v
8 Mar 22
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
f4k1ar8
8 Feb 22
Results of Operations and Financial Condition
1:44pm